Protective effect of a vitamin E analog, phosphatidylchromanol, against oxidative hemolysis of human erythrocytes

The protective effect of a vitamin E analog, phosphatidylchromanol [1,2‐diacyl‐ sn ‐glycero‐3‐phospho‐2′‐(hydroxyethyl)‐2′, 5′,7′,8′‐tetramethyl‐6′‐hydroxychroman; PCh], against oxidative hemolysis of human erythrocytes was examined and was compared with those of vitamin E (α‐tocopherol) and 2,2,5,7,8‐pentamethyl‐6‐chromanol (PMC). These three compounds at 50 μM protected the erythrocytes from hemolysis, when erythrocyte suspension (10%, vol/vol) was incubated with a water‐soluble radical generator, 2,2′‐azobis(2‐amidino‐propane)‐dihydrochloride (75 mM). When erythrocyte suspension was oxidized after pretreatment with these compounds (50 μM) for 30 min followed by washing, PCh protected about 54% of erythrocytes from the hemolysis, while α‐tocopherol protected only about 16% of the cells and PMC did not show any protective effect. During preincubation, α‐tocopherol, PMC, and PCh were incorporated into the cells at the concentration of 12.6, 3.7, and 16.3 nmol/mg protein, respectively. Moreover, PCh was found in the ghost membrane fraction at a 20% higher level than α‐tocopherol, and no PMC was detected in this fraction. These results indicate that phosphatidyl group in PCh accts as an excellent carrier of chromanol moiety into cells as well as an anchor within membranes more efficiently than phytyl group in α‐tocopherol. PMC seems to be slightly anchored within membranes because of the lack of hydrophobic side chain. The excellent antihemolytic activity of PCh is likely to be caused by its accumulation within erythrocyte membranes.